Digital Infuzion News

Tuesday, May 5, 2020

Digital Infuzion Develops COVID-19 Information Site for CEIRS

The Centers of Excellence for Influenza Research and Surveillance (CEIRS), while mainly focused on influenza virus research, are using their infrastructure and respiratory diseases expertise to respond to the world’s current threat, the SARS-CoV-2 virus that causes the COVID-19 disease. This change in focus is not an unfamiliar response for the CEIRS network, as it reacted similarly when the SARS epidemic hit the global in 2003. [1] As a branch of the National Institute of Allergy and Infectious Diseases (NIAID) tasked with studying and surveilling upper respiratory viruses, CEIRS has taken on various COVID-19 research efforts, and like many other research organizations, has worked to better characterize the virus’ behavior, pathogenicity, and genetic makeup.

Digital Infuzion manages the Data Processing and Coordinating Center (DPCC) on behalf of CEIRS. The DPCC coordinates the collection, standardization, and public dissemination of the scientific data created by CEIRS investigators. The DPCC also creates and manages outreach programs that communicate the goals, accomplishments, and resources created by CEIRS scientists. One of CEIRS' major information distribution mechanisms is the CEIRS website at

Given the significant contributions of CEIRS scientists to the advancement of knowledge of SARS-CoV-2, NIAID requested the creation of a new set of pages on the CEIRS website dedicated to this work. The pages, as well as new content on the CEIRS Home page, were launched by Digital Infuzion on April 13, 2020. While showing CEIRS COVID-19 research, the pages also provide real-time updates, curated Twitter content, and serve as a central source of CEIRS scientist’s publications and reagents resulting from their COVID-19 work.

In addition to the creation of CEIRS’ COVID-19 site, DPCC has also taken anticipatory measures to include additional data standards to accommodate the new strain in their data processing algorithms. These new data standards will ensure the accuracy of clinical trial and research data analysis as CEIRS works to mitigate the COVID-19 threat and forecast its spread.

Digital Infuzion is honored to have contributed, in our own way, to the work of CEIRS in their global fight against the COVID-19 pandemic and the impact of respiratory infectious diseases.
Author: Lyndi Scott

Categories: All Digital Infuzion News, Corporate NewsNumber of views: 4201